ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

ClinicalTrials.gov ID: NCT00257192

Public ClinicalTrials.gov record NCT00257192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

Study identification

NCT ID
NCT00257192
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
284 participants

Conditions and interventions

Conditions

Interventions

  • Ziprasidone oral capsules Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
13 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Feb 28, 2009
Completion
Feb 28, 2009
Last update posted
Mar 24, 2021

2006 – 2009

United States locations

U.S. sites
46
U.S. states
19
U.S. cities
37
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 35294-4400
Pfizer Investigational Site Birmingham Alabama 35294
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site Stanford California 94305
Pfizer Investigational Site Aurora Colorado 80045
Pfizer Investigational Site Washington D.C. District of Columbia 20010
Pfizer Investigational Site Altamonte Springs Florida 32701
Pfizer Investigational Site Fort Lauderdale Florida 33301
Pfizer Investigational Site North Miami Florida 33161
Pfizer Investigational Site Orange City Florida 32763
Pfizer Investigational Site Tampa Florida 33613
Pfizer Investigational Site Tavares Florida 32778
Pfizer Investigational Site Smyrna Georgia 30080
Pfizer Investigational Site Tucker Georgia 30084
Pfizer Investigational Site Honolulu Hawaii 96813
Pfizer Investigational Site Des Plaines Illinois 60016
Pfizer Investigational Site Oakbrook Terrace Illinois 60181
Pfizer Investigational Site Schaumburg Illinois 60194
Pfizer Investigational Site Pikesville Maryland 21208
Pfizer Investigational Site Towson Maryland 21204
Pfizer Investigational Site Towson Maryland 21286
Pfizer Investigational Site Clinton Township Michigan 48038
Pfizer Investigational Site Meridian Mississippi 39301
Pfizer Investigational Site Bridgeton Missouri 63044-2588
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Lincoln Nebraska 68510
Pfizer Investigational Site Omaha Nebraska 68131
Pfizer Investigational Site Buffalo New York 14209
Pfizer Investigational Site Buffalo New York 14215
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cincinnati Ohio 45224
Pfizer Investigational Site Cincinnati Ohio 45229
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Oklahoma City Oklahoma 73101
Pfizer Investigational Site Oklahoma City Oklahoma 73107
Pfizer Investigational Site Oklahoma City Oklahoma 73116
Pfizer Investigational Site Arlington Texas 76011
Pfizer Investigational Site DeSoto Texas 75115
Pfizer Investigational Site Plano Texas 75093
Pfizer Investigational Site Bothell Washington 98011
Pfizer Investigational Site Spokane Washington 99204
Pfizer Investigational Site Spokane Washington 99216
Pfizer Investigational Site Milwaukee Wisconsin 53226
Pfizer Investigational Site West Allis Wisconsin 53227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00257192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2021 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00257192 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →